Patents by Inventor Andrew D. J. Goodearl

Andrew D. J. Goodearl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tango 71 nucleic acids
    Patent number: 6416974
    Abstract: The invention relates to Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83 polypeptides, nucleic acid molecules encoding Tango-71, Tango-73, Tango-74, Tango-76, and Tango-83, and uses thereof.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: July 9, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas A. Holtzman, Andrew D. J. Goodearl
  • Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses
    Publication number: 20020086354
    Abstract: The invention relates to Tango-73, Tango-74, Tango-76, Tango-78, and Tango-83 polypeptides, nucleic acid molecules encoding Tango-73, Tango-74, Tango-76, Tango-78, and Tango-83, and uses thereof. The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided.
    Type: Application
    Filed: March 8, 2001
    Publication date: July 4, 2002
    Inventors: Douglas A. Holtzman, Andrew D.J. Goodearl, Sean A. McCarthy
  • Novel genes encoding proteins having prognostic, diagnostic, preventive , therapeutic and other uses
    Publication number: 20020028508
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: February 21, 2001
    Publication date: March 7, 2002
    Inventors: Douglas A. Holtzman, Andrew D.J. Goodearl, Sean A. McCarthy
  • Methods for detecting nucleic acid molecules encoding a member of the muscarinic family of receptors
    Patent number: 6093545
    Abstract: The invention provides methods for detecting the presence of a nucleic molecule encoding a muscarinic acetylcholine receptor 6 ("mACHR-6") family member.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: July 25, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew D. J. Goodearl, M. Alexandra Glucksmann
  • Nucleic acids encoding muscarinic receptors and uses therefor
    Patent number: 5882893
    Abstract: The invention provides isolated nucleic acids molecules, designated muscarinic acetylcholine receptor 6 ("mACHR-6") nucleic acid molecules, which encode polypeptides involved in the modulation of acetylcholine responses in acetylcholine responsive cells. The invention also provides antisense nucleic acid molecules, expression vectors containing mACHR-6 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an mACHR-6 gene has been introduced or disrupted. The invention still further provides isolated mACHR-6 polypeptides, fusion polypeptides, antigenic peptides, and anti-mACHR-6 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: March 16, 1999
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Andrew D.J. Goodearl
  • Schwann cell mitogenic factor, its preparation and use
    Patent number: 5594114
    Abstract: The invention provides a new Schwann cell-mitogenic factor of molecular weight about 43 to 45 kilodaltons, when isolated by SDS-PAGE. The invention provides therapeutic formulation comprising the new factor, and the use of the factor and the said formulations in treating conditions which involve a factor-sensitive or factor-responsive cell type.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: January 14, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Andrew D. J. Goodearl, Paul Stroobant, Michael D. Waterfield